Novel CDSCO and US FDA approved pneumonia drugs to ease public health challenge: Nandita Vijayasimha., Bengaluru Friday, December 13, 2024, 08:00 Hrs [IST] Indian healthcare provi ...

In this paper, we provide the first overview of the synergistic effects and potential mechanisms of MFL activity when used in combination with conventional antibiotics for treatment of MDR bacteria.

A new peptidoglycan hydrolase mined from Acinetobacter baumannii proteome by lysin-derived antimicrobial peptide-primed screening strategy undergoes a unique switch between dimer and monomer after ...

Zai Lab and Pfizer have entered a strategic collaboration to commercialise XACDURO (sulbactam-durlobactam), a new ...

In China specifically, Acinetobacter baumannii was the leading cause of ... we seek to bring this innovative treatment to Chinese patients more quickly, saving the lives of those most at risk.” ...

The first study evaluated the in vitro antimicrobial activity of eravacycline against Carbapenem-resistant Acinetobacter baumannii (CRAB), using broth microdilution ... XERAVA ® for injection is ...

“The collaboration with Zai Lab will help enable us to work together as we strive to address the growing problem of drug resistance in the treatment of Acinetobacter baumannii, and reflects the new ...

In the healthcare setting, A. baumannii is responsible for a wide range of infections, including bacteremia, pneumonia, meningitis, urinary tract infection and wound infection. The pathological ...

Building on previous work, researchers in ACS Infectious Diseases have demonstrated a potential antibacterial treatment from ... antibiotics to include Acinetobacter baumannii, Pseudomonas ...

First, in zebrafish embryos, D22 treatment cleared A. baumannii infection as effectively as ciprofloxacin, a broad-spectrum antibiotic used for complicated infections. Then the team conducted a ...

However, the most common pathogens were Acinetobacter baumannii and Klebsiella pneumoniae ... highlighting the need for faster diagnosis and treatment to prevent fatalities.

The goals include reducing antibiotic use in humans by 5 percent and reduce by 10 percent infections with carbapenem-resistant Acinetobacter baumannii, a highly antibiotic-resistant bacterium with ...